Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

DOI: 10.1016/j.clinthera.2014.12.013
Clinical Therapeutics, 2015, 37, 610-628.e4.

#	Paper	IF	Citations
35	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. *Annals of the New York Academy of Sciences*, **2015**, 1358, 28-43	6.5	63
34	Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. *Clinical Pharmacokinetics*, **2015**, 54, 1027-41	6.2	57
33	Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Clinical Pharmacokinetics*, **2015**, 54, 691-708	6.2	105
32	Renal effects of canagliflozin in type 2 diabetes mellitus. *Current Medical Research and Opinion*, **2015**, 31, 2219-31	2.5	42
31	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Advances in Therapy*, **2015**, 32, 1029-64	4.1	23
30	Mode of SGLT inhibition by an SGLT2 inhibitor, canagliflozin and implication in renal and small intestinal effects. *Folia Pharmacologica Japonica*, **2016**, 148, 245-252	0	
29	Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 358, 94-102	4.7	41
28	Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. *European Journal of Pharmaceutical Sciences*, **2016**, 93, 244-52	5.1	58
27	Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. *Advances in Therapy*, **2016**, 33, 1502-18	4.1	29
26	A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. *Biomedical Chromatography*, **2016**, 30, 1549-55	1.7	19
25	Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. *Clinical Therapeutics*, **2016**, 38, 89-98.e1	3.5	8
24	Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. *Clinical Pharmacokinetics*, **2016**, 55, 209-23	6.2	15
23	Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. *British Journal of Clinical Pharmacology*, **2017**, 83, 1072-1081	3.8	8
22	Canagliflozin: A Review in Type 2 Diabetes. *Drugs*, **2017**, 77, 1577-1592	12.1	21
21	The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. *Journal of Clinical Pharmacology*, **2017**, 57, 1432-1443	2.9	31
20	Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. *Diabetic Medicine*, **2018**, 35, 1037-1048	3.5	29
19	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease. *European Journal of Clinical Pharmacology*, **2019**, 75, 1481-1490	2.8	5

18	Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. *BMC Chemistry*, **2019**, 13, 82	3.7	13
17	Improving Drug Use and Dosing in Chronic Kidney Disease. **2019**, 250-272.e5		
16	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. *Journal of Endocrinological Investigation*, **2020**, 43, 289-304	5.2	15
15	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. *Drug Safety*, **2020**, 43, 1211-1221	5.1	12
14	Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. *Clinical Pharmacokinetics*, **2020**, 59, 981-994	6.2	6
13	Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. *Expert Opinion on Drug Safety*, **2020**, 19, 243-256	4.1	10
12	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. *Clinical Pharmacokinetics*, **2021**, 60, 517-525	6.2	0
11	An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 2087-2094	4	1
10	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. *Transplantation*, **2021**,	1.8	0
9	Antidiabetic agents in patients with hepatic impairment. *World Journal of Meta-analysis*, **2019**, 7, 380-388	0.5	3
8	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. *World Journal of Gastroenterology*, **2019**, 25, 3664-3668	5.6	5
7	Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. *Indian Journal of Endocrinology and Metabolism*, **2017**, 21, 341-354	1.7	29
6	Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. *World Journal of Hepatology*, **2020**, 12, 533-557	3.4	3
5	DIABETES MELLITUS IN PATIENTS WITH LIVER CIRRHOSIS: NEW TREATMENT OPTIONS. *Issledovaniĭ Praktika V Medicine*, **2017**, 4, 75-85	0.4	0
4	Hypoglycemic Therapy in Chronic Hepatic Disease Literature Review. *Open Journal of Endocrine and Metabolic Diseases*, **2020**, 10, 137-146	0.1	
3	Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. *P and T*, **2015**, 40, 451-62	1.4	37
2	Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. **2022**, 108330		0
1	Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18 F]Canagliflozin in Patients with Type 2 Diabetes.		0